相关临床试验
13
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
6
46.1%
终止
7
53.9%
暂无批准数据
- Titan Pharmaceuticals successfully completed its merger with Black Titan Corporation on October 1, 2025, becoming a wholly owned subsidiary of the combined entity. - The merged company's ordinary shares began trading on Nasdaq under the ticker symbol BTTC on October 2, 2025, following a one-for-one share conversion. - Black Titan CEO Chay W. J. described the merger as the beginning of a new chapter focused on innovation and global expansion to deliver transformative stakeholder value.
- Titan Pharmaceuticals completed two private placements with Blue Harbour Asset Management, raising a total of $1.6 million through convertible preferred stock offerings in April and June 2025. - The company issued 100,000 shares of Series B Convertible Preferred Stock at $3.00 conversion price and 60,000 shares of Series C at $3.40 conversion price. - Both preferred stock series include beneficial ownership conversion blockers preventing Blue Harbour from exceeding 19.99% of outstanding common stock or maximum Nasdaq-permissible percentages without shareholder approval. - The funding supports Titan's ongoing product development programs while providing strategic capital for regulatory approval processes and drug candidate advancement.
